Dr Ashwini Reddy

Dr Ashwini Reddy

Dr Ashwini Reddy

  • Interest Area: Immunology Oncology, Rare Diseases, Translational Medicine, Vaccines
  • Senior Fellow: Institute of Health Economics Epidemiology and Translational Sciences (IHEETS)
  • info@iheets.co.in
Institute of Health Economics Epidemiology and Translational Sciences (IHEETS)

New Delhi

Profile Summary

Over 15 years of global experience in Medical Affairs, Medical Communications, Clinical Operations, and Strategic Medical Planning within the pharmaceutical, biotechnology and life sciences industry.

  • Leading Medical Affairs & Medical Communications at Neovation Consultancy Services, managing key projects for top-tier pharma clients with a focus on executional excellence, compliance and innovation.
  • Specialized in various disease & therapeutic areas to note in Immunology Oncology, Rare Diseases, Translational Medicine and Vaccines, with strong capabilities in medical affairs, medical communications, clinical trial management, regulatory alignment, and cross-functional leadership.
  • Proven success in integrating AI technologies to enhance Medical Communications, Project & Program Management and Agile Operational Efficiency.
  • Known for a strong Strategic Mindset, Scientific Acumen, Stakeholder Engagement & Operational Excellence driving impactful and compliant healthcare solutions across the globe.

Work Experience

Head Medical Affairs (India)

Since 2024 | Neovation Consultancy Services Pte. Ltd, Singapore

Key Result Areas:

  • Currently spearheading multiple Medical Affairs and Medical Communication initiatives (content, events, digital engagements & innovation) for top-tier global pharmaceutical multinationals, driving strategic alignment, operational excellence, business development & cross-functional and cross-country collaborations.

Global Rare Diseases Program Manager

2022-2023 | Sanofi Healthcare Pvt. Ltd., Hyderabad

Key Result Areas:

  • Managed and executed global medical affairs projects for rare diseases (ASMD, Gaucher, Fabry, Pompe), managing cross-functional teams, and stakeholder engagement across projects.
  • Oversaw vendor coordination, launched educational platforms, and implemented governance to drive operational efficiency.

Global Engagement & Medical Education:

  • Launched the Gaucher Leadership Forum on a global university platform, reaching stakeholders in over 112 countries.
  • Orchestrated international medical symposiums, webinars, and advisory boards to disseminate clinical insights and align strategic goals.

Senior Manager Medical Affairs (COVAXIN Lead)

2020-2022 | Bharat Biotech International Ltd., Hyderabad

Clinical Development Leadership – COVAXIN:

  • Led the end-to-end clinical development of COVAXIN across Phases I–III for both adult and pediatric populations.
  • Spearheaded the design and implementation of medical strategies for intranasal and intradermal SARS-CoV-2 vaccine platforms.

Strategic Medical Engagement & Advocacy:

  • Directed key opinion leader (KOL) engagements to shape medico-marketing strategies and advocacy initiatives.
  • Managed post-approval medical affairs activities, including Continuing Medical Education (CME) programs and support for global product launches.

Career Timeline

Since 2024Neovation Consultancy Services, Mumbai
2022-2023Sanofi Healthcare Pvt. Ltd., Hyderabad
2020-2022Bharat Biotech International Ltd., Hyderabad
2019-2020Novartis Healthcare Pvt. Ltd., Hyderabad
2016-2019Institute of Immunology, NUIM, Ireland

Selected Publications

  • Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152). Lancet. 2021 Dec 11;398(10317):2173-2184. click to read more...
  • Reddy R, Reddy B, et al. A multi-centre, post-marketing surveillance study of Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®) in India. Hum Vaccin Immunother. 2022;18(1):1947761. click to read more...
  • Gullo G, J Eustace A, et al. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer. Ther Adv Med Oncol. 2019 Jul 24;11:1758835919864236. click to read more...
  • Gupta, Saket. Analysis of Inflammatory Cytokines in Pre-Diabetic Subjects. Current Research in Diabetes & Obesity Journal, 2017. click to read more...
  • Gupta S, Maratha A, Siednienko J, et al. Analysis of inflammatory cytokine and TLR expression levels in Type 2 Diabetes with complications. Sci Rep. 2017 Aug 9;7(1):7633. click to read more...
  • O'Farrell AC, Evans R, Silvola JM, et al. A Novel PET Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate. PLoS One. 2017 Jan 27;12(1):e0169964. click to read more...
  • Maratha A, Colhoun HO, et al. Classical Galactosaemia and CDG, the N-Glycosylation Interface. A Review. JIMD Rep. 2017;34:33-42. click to read more...
  • Maratha A, Stockmann H, et al. Classical galactosaemia: novel insights in IgG N-glycosylation and N-glycan biosynthesis. Eur J Hum Genet. 2016 Jul;24(7):976-84. click to read more...
  • Stockmann H, Coss KP, et al. IgG N-Glycosylation Galactose Incorporation Ratios for the Monitoring of Classical Galactosaemia. JIMD Rep. 2016;27:47-53. click to read more...
  • COLHOUN, Hugh Owen et al. The Leptin System in Patients with Classical Galactosaemia. Medical Research Archives, 2015. click to read more...
  • Connolly M, Rooney PR, et al. Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms. Ann Rheum Dis. 2016 Jul;75(7):1392-8. click to read more...
  • Lanigan F, Brien GL, et al. Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients. FEBS J. 2015 Sep;282(18):3455-73. click to read more...
  • Ahmed S, Maratha A, et al. TRIF-mediated TLR3 and TLR4 signaling is negatively regulated by ADAM15. J Immunol. 2013 Mar 1;190(5):2217-28. click to read more...
  • Siednienko J, Maratha A, et al. Nuclear factor κB subunits RelB and cRel negatively regulate Toll-like receptor 3-mediated β-interferon production. J Biol Chem. 2011 Dec 30;286(52):44750-63. click to read more...

Memberships

Gaucher Leadership Forum Osteoarthritis Research Society International Irish Society for Immunology Irish Endocrine Society Irish Cancer Society